Skip to main content
. Author manuscript; available in PMC: 2019 Nov 15.
Published in final edited form as: Trends Cancer Res. 2019;14:1–9.

Figure 2.

Figure 2.

TDO2 and IDO1 levels in ovarian cancer patients from the Tothill cohort (n = 293). RNA expression was compared between (A) disease stage, (B) recurrence status, and (C) the five-year survival rate of patients with high versus low levels of expression based on the median. Comparisons were statistically analyzed using one-way ANOVA for disease stage (TDO2 p = 0.003, IDO1 p = 0.262), unpaired t-test for recurrence, and log-rank for survival; mean ± standard deviation, * p < 0.05, ** p < 0.01.